Oncternal Historical Income Statement

ONCT Stock

USD 0.69 0.06 8.00%

Historical analysis of Oncternal Therapeutics income statement accounts such as Research Development of 25.1 M can show how well Oncternal Therapeutics performed in making a profits. Evaluating Oncternal Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Oncternal Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oncternal Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncternal Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

About Oncternal Income Statement Analysis

Oncternal Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Oncternal Therapeutics shareholders. The income statement also shows Oncternal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Oncternal Therapeutics Income Statement Chart

At this time, Oncternal Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 847.7 K in 2024, whereas EBIT is likely to drop (41.5 M) in 2024.

Other Operating Expenses Research Development Total Operating Expenses Selling General Administrative Net Income From Continuing Ops

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Oncternal Therapeutics. It is also known as Oncternal Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Oncternal Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Oncternal Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.At this time, Oncternal Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 847.7 K in 2024, whereas EBIT is likely to drop (41.5 M) in 2024.

	2010	2023	2024 (projected)
Reconciled Depreciation	47K	41.4K	37.2K
Discontinued Operations	13.9M	12.5M	11.1M

Reconciled Depreciation Discontinued Operations

Oncternal Therapeutics income statement Correlations

	Depreciation And Amortization	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Selling General Administrative	Income Before Tax	Total Other Income Expense Net	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Discontinued Operations	Reconciled Depreciation	Net Interest Income	Interest Income	Non Recurring	Selling And Marketing Expenses
Depreciation And Amortization		0.12	-0.34	-0.27	0.09	0.7	-0.49	-0.28	-0.96	0.09	-0.03	0.15	0.0	-0.88	0.93	-0.4	-0.02	-0.91	-0.92	0.93	0.93	-0.91	-0.91
Other Operating Expenses	0.12		-0.88	-0.86	0.99	-0.53	0.78	-0.83	-0.15	0.88	0.22	0.02	0.11	-0.1	0.08	-0.55	-0.02	-0.18	-0.17	0.28	0.28	-0.18	-0.18
Operating Income	-0.34	-0.88		0.96	-0.9	0.4	-0.62	0.82	0.36	-0.7	-0.24	0.0	0.11	0.36	-0.26	0.66	0.07	0.32	0.34	-0.4	-0.4	0.32	0.32
Ebit	-0.27	-0.86	0.96		-0.87	0.49	-0.64	0.71	0.35	-0.69	-0.32	-0.24	0.09	0.29	-0.19	0.5	-0.19	0.25	0.27	-0.33	-0.33	0.25	0.25
Research Development	0.09	0.99	-0.9	-0.87		-0.56	0.8	-0.82	-0.12	0.84	0.17	0.0	0.05	-0.09	0.05	-0.59	-0.03	-0.14	-0.15	0.25	0.25	-0.14	-0.14
Ebitda	0.7	-0.53	0.4	0.49	-0.56		-0.92	0.27	-0.61	-0.43	-0.27	-0.05	0.07	-0.58	0.7	0.01	-0.15	-0.63	-0.63	0.59	0.59	-0.63	-0.63
Total Operating Expenses	-0.49	0.78	-0.62	-0.64	0.8	-0.92		-0.54	0.44	0.7	0.24	-0.1	0.11	0.46	-0.51	-0.27	-0.04	0.41	0.42	-0.36	-0.36	0.41	0.41
Net Income	-0.28	-0.83	0.82	0.71	-0.82	0.27	-0.54		0.18	-0.75	-0.23	0.2	0.02	0.31	-0.27	0.66	0.27	0.36	0.37	-0.44	-0.44	0.36	0.36
Income Tax Expense	-0.96	-0.15	0.36	0.35	-0.12	-0.61	0.44	0.18		-0.09	-0.01	-0.35	0.03	0.86	-0.88	0.3	-0.2	0.85	0.86	-0.89	-0.89	0.85	0.85
Selling General Administrative	0.09	0.88	-0.7	-0.69	0.84	-0.43	0.7	-0.75	-0.09		0.35	0.01	0.43	0.09	0.01	-0.37	-0.01	-0.08	-0.1	0.22	0.22	-0.08	-0.08
Income Before Tax	-0.03	0.22	-0.24	-0.32	0.17	-0.27	0.24	-0.23	-0.01	0.35		0.24	0.0	0.01	0.08	0.5	0.24	0.05	0.02	-0.09	-0.09	0.05	0.05
Total Other Income Expense Net	0.15	0.02	0.0	-0.24	0.0	-0.05	-0.1	0.2	-0.35	0.01	0.24		-0.05	-0.16	0.15	0.38	0.98	-0.18	-0.17	0.2	0.2	-0.18	-0.18
Total Revenue	0.0	0.11	0.11	0.09	0.05	0.07	0.11	0.02	0.03	0.43	0.0	-0.05		0.41	-0.05	0.03	-0.04	0.03	0.0	-0.05	-0.05	0.03	0.03
Gross Profit	-0.88	-0.1	0.36	0.29	-0.09	-0.58	0.46	0.31	0.86	0.09	0.01	-0.16	0.41		-0.89	0.37	0.0	0.82	0.82	-0.85	-0.85	0.82	0.82
Cost Of Revenue	0.93	0.08	-0.26	-0.19	0.05	0.7	-0.51	-0.27	-0.88	0.01	0.08	0.15	-0.05	-0.89		-0.26	-0.01	-0.88	-0.9	0.87	0.87	-0.88	-0.88
Net Income From Continuing Ops	-0.4	-0.55	0.66	0.5	-0.59	0.01	-0.27	0.66	0.3	-0.37	0.5	0.38	0.03	0.37	-0.26		0.46	0.38	0.39	-0.48	-0.48	0.38	0.38
Non Operating Income Net Other	-0.02	-0.02	0.07	-0.19	-0.03	-0.15	-0.04	0.27	-0.2	-0.01	0.24	0.98	-0.04	0.0	-0.01	0.46		-0.01	-0.01	0.03	0.03	-0.01	-0.01
Discontinued Operations	-0.91	-0.18	0.32	0.25	-0.14	-0.63	0.41	0.36	0.85	-0.08	0.05	-0.18	0.03	0.82	-0.88	0.38	-0.01		0.98	-0.93	-0.93	1.0	1.0
Reconciled Depreciation	-0.92	-0.17	0.34	0.27	-0.15	-0.63	0.42	0.37	0.86	-0.1	0.02	-0.17	0.0	0.82	-0.9	0.39	-0.01	0.98		-0.93	-0.93	0.98	0.98
Net Interest Income	0.93	0.28	-0.4	-0.33	0.25	0.59	-0.36	-0.44	-0.89	0.22	-0.09	0.2	-0.05	-0.85	0.87	-0.48	0.03	-0.93	-0.93		1.0	-0.93	-0.93
Interest Income	0.93	0.28	-0.4	-0.33	0.25	0.59	-0.36	-0.44	-0.89	0.22	-0.09	0.2	-0.05	-0.85	0.87	-0.48	0.03	-0.93	-0.93	1.0		-0.93	-0.93
Non Recurring	-0.91	-0.18	0.32	0.25	-0.14	-0.63	0.41	0.36	0.85	-0.08	0.05	-0.18	0.03	0.82	-0.88	0.38	-0.01	1.0	0.98	-0.93	-0.93		1.0
Selling And Marketing Expenses	-0.91	-0.18	0.32	0.25	-0.14	-0.63	0.41	0.36	0.85	-0.08	0.05	-0.18	0.03	0.82	-0.88	0.38	-0.01	1.0	0.98	-0.93	-0.93	1.0

Click cells to compare fundamentals

Oncternal Therapeutics Account Relationship Matchups

Oncternal Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	18.3M	150K	33K	702K	41.7M	43.8M
Other Operating Expenses	15.0M	17.5M	31.4M	44.9M	42.5M	36.2M
Operating Income	(33.1M)	(17.5M)	(31.4M)	(44.9M)	(41.7M)	(43.8M)
Ebit	(33.1M)	(17.5M)	(31.4M)	(44.9M)	(39.5M)	(41.5M)
Research Development	10.2M	12.5M	24.1M	33.0M	29.8M	25.1M
Ebitda	(14.8M)	(17.5M)	(31.3M)	(44.2M)	2.2M	2.3M
Total Operating Expenses	15.0M	17.5M	31.4M	44.9M	12.7M	12.1M
Net Income	(15.9M)	(17.2M)	(31.3M)	(43.4M)	(39.5M)	(41.5M)
Income Tax Expense	(18.3M)	(16K)	(33K)	(777K)	(41.7M)	(39.6M)
Selling General Administrative	7.3M	8.4M	11.6M	13.5M	12.5M	9.5M
Income Before Tax	(34.2M)	(17.2M)	(31.3M)	(44.2M)	(39.5M)	(41.5M)
Total Other Income Expense Net	(1.1M)	317K	33K	777K	2.2M	2.3M
Total Revenue	2.4M	3.4M	4.3M	1.5M	785K	745.8K
Gross Profit	(7.7M)	3.4M	4.3M	1.5M	(29.0M)	(27.5M)
Cost Of Revenue	10.2M	12M	169K	179K	29.8M	31.2M
Net Income From Continuing Ops	(34.2M)	(17.2M)	(31.3M)	(44.2M)	(41.7M)	(43.8M)
Non Operating Income Net Other	641K	(1.1M)	317K	786K	903.9K	503.1K
Net Income Applicable To Common Shares	(34.2M)	(17.2M)	(31.3M)	(44.2M)	(50.8M)	(53.3M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Oncternal Stock Analysis

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncternal Historical Income Statement

About Oncternal Income Statement Analysis

Oncternal Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Oncternal Therapeutics income statement Correlations

Oncternal Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncternal Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Oncternal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Other Operating Expenses	Operating Income
Ebit	Research Development
Ebitda	Total Operating Expenses
Net Income	Income Tax Expense
Selling General Administrative	Income Before Tax
Total Other Income Expense Net	Total Revenue
Gross Profit	Cost Of Revenue
Net Income From Continuing Ops	Non Operating Income Net Other
Net Income Applicable To Common Shares	Discontinued Operations
Reconciled Depreciation	Net Interest Income
Interest Income	Non Recurring
Selling And Marketing Expenses

Non Recurring	+ 1.0	Discontinued Operations
Selling And Marketing Expenses	+ 1.0	Discontinued Operations
Interest Income	+ 1.0	Net Interest Income
Selling And Marketing Expenses	+ 1.0	Non Recurring
Research Development	+ 0.99	Other Operating Expenses
Non Operating Income Net Other	+ 0.98	Total Other Income Expense Net

Income Tax Expense	- 0.96	Depreciation And Amortization
Selling And Marketing Expenses	- 0.93	Interest Income
Non Recurring	- 0.93	Interest Income
Selling And Marketing Expenses	- 0.93	Net Interest Income
Non Recurring	- 0.93	Net Interest Income
Interest Income	- 0.93	Reconciled Depreciation